You are here:
Clinical Trials and Outcomes Branch
Health outcomes represent all physical and social consequences of disease. These include symptoms, functioning, costs, complications of treatment, and mortality.
The overall goals of our research effort are:
- Understand the factors that influence health outcomes of patients with systemic lupus erythematosus, ankylosing spondylitis, and rheumatoid arthritis
- Develop new tools and techniques to measure outcomes in these diseases
- Assess rheumatic disease in an underserved minority community
- Compare outcomes among patients having orthopedic surgery
Patient-related factors, such as demographic characteristics, genetic background, and treatment, influence health outcomes. Certain provider-related factors, including access to care, also influence heath outcomes. We are studying genetic, clinical, and treatment influences on functional and structural outcomes in ankylosing spondylitis, and provider influences on outcomes in patients with lupus nephritis and hospitalized patients with systemic lupus erythematosus. Among measures of health outcomes, we are testing criteria for clinically important changes in symptoms in patients with rheumatoid arthritis, and are developing methods to quantify the progression of spinal fusion in patients with ankylosing spondylitis. We are examining associations between chronic bisphosphonate use and bone structure and risk of hip fracture.
Chen F, Wang Z, Bhattacharyya T. Absence of femoral cortical thickening in long-term bisphosphonate users: implications for atypical femur fractures. Bone. 2014 May;62:64-6. doi: 10.1016/j.bone.2014.01.011. Epub 2014 Jan 25.
Wang Z, Anderson FA Jr, Ward M, Bhattacharyya T. Surgical Site Infections and Other Postoperative Complications following Prophylactic Anticoagulation in Total Joint Arthroplasty. PLoS One. 2014 Apr 9;9(4):e91755. doi: 10.1371/journal.pone.0091755. eCollection 2014.
International Genetics of Ankylosing Spondylitis Consortium (IGAS), Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, Leo P, Cremin K, Pryce K, Harris J, Lee S, Joo KB, Shim SC, Weisman M, Ward M, Zhou X, Garchon HJ, Chiocchia G, Nossent J, Lie BA, Førre O, Tuomilehto J, Laiho K, Jiang L, Liu Y, Wu X, Bradbury LA, Elewaut D, Burgos-Vargas R, Stebbings S, Appleton L, Farrah C, Lau J, Kenna TJ, Haroon N, Ferreira MA, Yang J, Mulero J, Fernandez-Sueiro JL, Gonzalez-Gay MA, Lopez-Larrea C, Deloukas P, Donnelly P; Australo-Anglo-American Spondyloarthritis Consortium (TASC); Groupe Française d'Etude Génétique des Spondylarthrites (GFEGS); Nord-Trøndelag Health Study (HUNT); Spondyloarthritis Research Consortium of Canada (SPARCC); Wellcome Trust Case Control Consortium 2 (WTCCC2), Bowness P, Gafney K, Gaston H, Gladman DD, Rahman P, Maksymowych WP, Xu H, Crusius JB, van der Horst-Bruinsma IE, Chou CT, Valle-Oñate R, Romero-Sánchez C, Hansen IM, Pimentel-Santos FM, Inman RD, Videm V, Martin J, Breban M, Reveille JD, Evans DM, Kim TH, Wordsworth BP, Brown MA. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013 Jul;45(7):730-8. doi: 10.1038/ng.2667. Epub 2013 Jun 9.
Bethi S, Dasgupta A, Weisman MH, Learch TJ, Gensler LS, Davis JC Jr, Reveille JD, Ward MM. Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: are focused measures more informative? Arthritis Care Res (Hoboken). 2013 Apr;65(4):607-14. doi: 10.1002/acr.21878.
Wasko MC, Dasgupta A, Hubert H, Fries JF, Ward MM. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum. 2013 Feb;65(2):334-42. doi: 10.1002/art.37723.
Ward MM, Learch TJ, Gensler LS, Davis JC Jr, Reveille JD, Weisman MH. Regional radiographic damage and functional limitations in patients with ankylosing spondylitis: differences in early and late disease. Arthritis Care Res (Hoboken). 2013 Feb;65(2):257-65. doi: 10.1002/acr.21821.See extended list of publications
Updated October 21, 2015